VIA
RYTM icon

Virtus Investment Advisers’s Rhythm Pharmaceuticals RYTM Stock Holding History

Virtus Investment Advisers’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$647K Buy
7,434
+1,417
+24% +$138K 0.18% 186
2025
Q4 		$644K Sell
6,017
-1,035
-15% -$110K 0.18% 207
2025
Q3 		$712K Hold
7,052
– – 0.2% 166
2025
Q2 		$446K Buy
7,052
+606
+9% +$37.1K 0.15% 201
2025
Q1 		$341K Buy
+6,446
New +$358K 0.09% 231

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Virtus Investment Advisers's RYTM Position: Q1 2026 in Review

Virtus Investment Advisers increased its Rhythm Pharmaceuticals (RYTM) stake by 24% in Q1 2026, buying an estimated $138K and bringing the position to 7,434 shares worth $647K. The position accounts for 0.18% of the portfolio, ranked #186.

Virtus Investment Advisers first reported a position in RYTM in Q1 2025 and has held it in 5 quarters since. The position peaked at $712K in Q3 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Virtus Investment Advisers held 7,434 shares of Rhythm Pharmaceuticals worth $647K as of Q1 2026.
  • Virtus Investment Advisers bought 1,417 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $138K.
  • Rhythm Pharmaceuticals made up 0.18% of Virtus Investment Advisers's portfolio in Q1 2026, its #186 holding.
  • Virtus Investment Advisers first reported a position in Rhythm Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Virtus Investment Advisers's Rhythm Pharmaceuticals position peaked at $712K in Q3 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.